What question did this study set out to answer?

To describe the clinical characteristics, treatment patterns, and outcomes for high-risk ER+/HER2- breast cancer patients treated with neoadjuvant chemotherapy.

February 19, 2026Clinical Cancer Research

Abstract PS3-09-26: Real-world clinical characteristics, treatment patterns and outcomes among UK and French patients with early-stage, estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer treated with neoadjuvant chemotherapy

View Full Paper

Ask AI

Bookmark

To describe the clinical characteristics, treatment patterns, and outcomes for high-risk ER+/HER2- breast cancer patients treated with neoadjuvant chemotherapy.
Observational, retrospective cohort study utilizing electronic health records from oncology centers in France and the UK
Included patients with high-risk, early-stage ER+/HER2- breast cancer initiating neoadjuvant chemotherapy
Descriptive statistics were used to summarize demographics, treatments, and real-world pathological complete response
The cohort included 281 patients, with 83.7% being ER-positive and 90.4% having an ECOG score of 0
The most prescribed neoadjuvant chemotherapy agents were anthracycline with cyclophosphamide, often combined with a taxane
Only 10.3% of patients achieved real-world pathological complete response, indicating a high unmet need for effective therapies

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Observational cohort study examines outcomes in high-risk ER+/HER2- breast cancer patients receiving neoadjuvant chemotherapy, suggesting treatment improvements are needed.

Cite This Study

Hall et al. (2026) studied this question.

synapsesocial.com/papers/6996a8a9ecb39a600b3efa19 https://doi.org/10.1158/1557-3265.sabcs25-ps3-09-26

View Full Paper

Ask AI

Bookmark

Implication

Observational cohort study examines outcomes in high-risk ER+/HER2- breast cancer patients receiving neoadjuvant chemotherapy, suggesting treatment improvements are needed.

Abstract PS3-09-26: Real-world clinical characteristics, treatment patterns and outcomes among UK and French patients with early-stage, estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer treated with neoadjuvant chemotherapy

Key Points

Discussion

Implication

Cite This Study

Abstract PS3-09-26: Real-world clinical characteristics, treatment patterns and outcomes among UK and French patients with early-stage, estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer treated with neoadjuvant chemotherapy

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider